Urology Research Center, Tehran University of Medical Sciences
Translational Research in Urology
2717-042X
3
1
2021
01
01
Knockout Serum Replacement as a Substitute for Exosome Free Serum
1
3
EN
Keykavos
Gholami
1.Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran.
keykavosgholami@yahoo.com
10.22034/TRU.2020.262287.1056
Exosomes, extracellular vesicles secreted from cells, are carriers containing proteins, lipids, and nucleic acids. By adhering and releasing their contents to the recipient cells, exosomes play a major role in cellular communication. Based on a variety of their originated cells, cargos, and physiologic state of releasing cell, Exosomes have been attributed to an extended range of roles such as signal transduction, reprogramming, epigenetic modification, and inflammation. Recently, it has been shown that exosomes are also involved in pathological mechanisms of diseases, such as neurodegenerative diseases, tumors, chronic inflammation, and cardiovascular diseases. Moreover, exosomes have been used as diagnostic markers for different diseases since their cargos and contents can reflect the physiological or pathological processes of the cells of origin. Because of having features of being carriers, they can be considered a vehicle for drug delivery or gene therapy.
Exosome,Fetal Bovine Serum,Knockout Serum Replacement,Purification
http://www.transresurology.com/article_121000.html
http://www.transresurology.com/article_121000_0d97cd51e8bd972be9b7d51ed7f01c94.pdf
Urology Research Center, Tehran University of Medical Sciences
Translational Research in Urology
2717-042X
3
1
2021
01
01
Combined Direct Visual and Imaging Guided Percutaneous Nephrolithotomy: A Novel Technique
4
9
EN
Hamidreza
Zia
0000-0002-2335-4843
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
ziahamidreza@gmail.com
Fatemeh
Khatami
0000-0002-6311-1336
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
fatemehkhatami1978@gmail.com
Mohammad Reza
Rahimi
0000000262814195
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
mrrhmi@gmail.com
Seyed Mohammad Kazem
Aghamir
0000-0003-1611-0362
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
mkaghamir@tums.ac.ir
10.22034/tru.2020.257597.1051
<strong>Introduction</strong><br />Percutaneous nephrolithotomy (PCNL) is a common urological procedure. Obtaining secure percutaneous access to the collecting system which is usually done under fluoroscopic guidance and tract dilatation is a crucial step toward a successful and safe procedure. This study aims to introduce a novel technique to modify this procedure.<br /><strong>Method</strong><br />Combined Direct Visual and Imaging Guided PCNL is performed by using specific 28 Fr dilatators with a customized central lumen that accepts a 4.5 F semi-rigid ureteroscope to visually confirm the puncture of the target calyx and passing a guidewire. This instrument was passed as a one-shot dilator after the withdrawal of the puncture needle. The rest of the procedure was then carried out in a standard manner. This novel technique was introduced to 12 patients in 2020 in Sina hospital, after completing the informed consent.<br /><strong>Results </strong><br />The mean age was 53.58±11.96 and the average stone size was 4.1±0.58 cm and the average time from insertion of the needle into the target calyx until securing a guide wire inside the collecting system (pelvis, ureter) was 95 seconds (84-107). Fluoroscopy time (total time required to obtain the access but not the whole operation) was on average 30.25±8.01 seconds. There were no intraoperative or postoperative complications as a result of this technique.<br /><strong>Conclusions</strong><br />The use of the ureteroscope loaded with the dilator and sheath during PNCL seems to be a feasible and safe technique for dilatation of the access tract during one shot PCNL.
Technique,Percutaneous,nephrolithotomy,Nephrolithiasis,Iran
http://www.transresurology.com/article_119768.html
http://www.transresurology.com/article_119768_5017e52f9cb05027fbc10a8e29ed73c3.pdf
Urology Research Center, Tehran University of Medical Sciences
Translational Research in Urology
2717-042X
3
1
2021
01
01
A Systematic Review of Circulating Tumor Cells in Renal Cell Carcinoma
10
18
EN
Seyed Mohammad Kazem
Aghamir
0000-0003-1611-0362
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
mkaghamir@tums.ac.ir
Mohadeseh
Nasir Shirazi
Monoclonal antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
m.nasirshirazi25@gmail.com
Fatemeh
Khatami
0000-0002-6311-1336
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
fatemehkhatami1978@gmail.com
10.22034/tru.2020.257587.1050
<strong>Introduction</strong><br />Renal cell carcinoma (RCC) is one of the most usual kidney’s tumors. The improvement of non-invasive biomarkers will make it feasible to investigate whose have high risk of recurrence after radical or partial nephrectomy and will expand the valuation of tumor response to several treatment strategies. In this perspective, liquid biopsy suggests a talented perception for cancer diagnosis and monitoring, with several benefits versus traditional RCC diagnostic processes and can be taken into account of the present RCC diagnosis and controlling strategies.<br /><strong>Method</strong><br />In this systematic review, we considered both CTCs count and molecular markers in RCC patient management. A systematic search on several databases like PubMed, Scopus, Embase, and Web of Science was directed which led to the final 24 studies considering the impact of CTCs on both diagnosis and prognosis of RCC.<br /><strong>Results</strong><br />Several primary studies consider the CTCs quantitation as the tumor representing components that are based on immunomagnetic separation procedure. The magnetic cell sorting (MACS) technique, cell search, Tapered-slit filter (photosensitive polymer-based microfilter), CELLection™ Dynabeads® coated with the monoclonal antibodies, and ISET® -Isolation by Size of Tumor cells. If CTCs wanted to be recruited for the prognosis of RCC and progression-free survival (PFS) it is better to check by gene expression profile through quantitative polymerase chain reaction analysis (Real Time-PCR) or in situ hybridization of CTC’s RNA molecules. <br /><strong>Conclusions</strong><br />CTCs detection as the main liquid biopsy component has an excessive clinical impact on cancer management. Nevertheless, usual methods have some limitations when directing for the recognition of circulating tumor cells (CTCs) with high efficiency and low cost. Some CTCs molecular markers and gene expression profiling of CTCs should be considered for RCC prognosis.
renal cell carcinoma,circulating tumor cells,Molecular markers,Diagnosis
http://www.transresurology.com/article_120190.html
http://www.transresurology.com/article_120190_118d40bc6ba5098294b24de7c23a15d8.pdf
Urology Research Center, Tehran University of Medical Sciences
Translational Research in Urology
2717-042X
3
1
2021
01
01
Successful En-Bloc Kidney Transplantation from a 5-year-Old Donor with Cerebral Palsy to a 60-Year Old Recipient: A Case Report
19
22
EN
Mohammad Hatef
Khorrami
0000-0003-1246-6345
Isfahan University of Medical Sciences, Isfahan, Iran
khorramimohammadhatef@gmail.com
Sanaz
Dehghani
0000-0001-5946-2611
Organ procurement unit of Sina hospital, Tehran University of Medical Sciences, Tehran, Iran
dehghanis914@gmail.com
Rahil
Mashhadi
0000-0003-1788-5282
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
rh_mashhadi@yahoo.com
Hossein
Abdi
0000-0003-4292-3199
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
abdihossein96@gmail.com
Farshad
Namdari
0000-0002-4813-2665
Aja university of medical sciences, Tehran, Iran
namdari537@gmail.com
10.22034/tru.2021.257484.1049
<strong>Introduction</strong><br />There are a growing number of unmet kidney donor sources. So, alternative donor sources, such as donation after circulatory determination of death (DCDD), are taken into the consideration.<br /><strong>Case presentation</strong><br />In this study, we represent successful En-Bloc kidney transplantation from a 4-year-Old donor with cerebral palsy to a 60-year old recipient. The kidney of a 4-year-old boy with congenital CP (weight=12Kg; BMI=12) with brain death was transplanted to a 60-year-old man (weight =70Kg; BMI=23.6). Panel-reactive antibody (PRA) to HLA class I (PRA I) and HLA class II (PRA II) were observed less than 5% in the 60-year old recipient. Also, the PRA titer with complement-dependent cytotoxicity (PRA-CDC) and the donor-recipient WBC crossmatch was negative. Our case is reported by a successful EKBT to an adult with the en-bloc kidney of a 4-year-old child with cerebral palsy. The small kidneys of a cerebral palsy child are adapting and functioning well in the adult body.<br /><strong>Conclusions</strong><br />Therefore, CP pediatric donors can be good resources for transplantation whenever available.
kidney transplant,pediatric donors,Organ donation,Circulatory Determination of Death
http://www.transresurology.com/article_125042.html
http://www.transresurology.com/article_125042_54a43497f22e0695705cd3eaf79f94d1.pdf
Urology Research Center, Tehran University of Medical Sciences
Translational Research in Urology
2717-042X
3
1
2021
01
01
Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction
23
31
EN
Seyed Amin
Mirsadeghi
0000-0001-9601-1588
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
dr.mirsadeghi@gmail.com
Seyed Saeed
Tamehri Zadeh
0000-0001-7803-5850
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
tamehrysaeed@gmail.com
Alimohammad
Fakhr Yasseri
0000-0003-2084-2814
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
yasseri_2006@yahoo.com
Ali
Tabibi
0000-0003-2829-6061
Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences Tehran, Iran
tabibiali06@gmail.com
Mohammad Hadi
Radfar
0000-0002-6820-6350
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
mhadirad@yahoo.com
Diana
Taheri
0000-0002-8131-1120
Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
diana1380@yahoo.com
10.22034/tru.2021.256708.1042
<strong>Introduction</strong><br />To compare the effectiveness of tamsulosin and Tolterodine in reducing stent-related symptoms with each other and with the control group we performed this randomized clinical trial.<br /><strong>Methods</strong><br />150 patients after successful first-time transurethral lithotripsy (TUL) for unilateral ureteral stones were elected for the study 17 patients were excluded in the first allocation. Other patients were randomized (With balanced blocked randomization) into three groups. In group 1, 41 patients received Tamsulosin (Omnic) 0.4mg once a day for a month and in group 2, 42 patients received tolterodine (Detrusitol) 2mg once a day for a month. In group 3, which was our control group, 50 patients received a placebo once a day for a month. Clinical stent-related symptoms questionnaires at the first visit (day 10) and before removing themes stent were completed. Two urine tests and an x-ray of the abdomen in the first visit have been performed.<br /><strong>Results</strong><br />Despite the remarkable decrease in the severity of stent-related symptoms other than urine urgency in the control group (p-value<0.05), solitary use of neither tamsulosin nor tolterodine was superior to the control group, and also, they were not superior to each other with respect to improving double-J stent-related symptoms (p-value>0.05).<br /><strong>Conclusion</strong><br />The results of our study show that the administration of tolterodine and tamsulosin to reduce stent-related symptoms do not have superiority over each other and the control group.
ureteral stent,tamsulosin,tolterodine
http://www.transresurology.com/article_125425.html
http://www.transresurology.com/article_125425_f5a45557dbca4301b2aed944b1cbcdf2.pdf
Urology Research Center, Tehran University of Medical Sciences
Translational Research in Urology
2717-042X
3
1
2021
01
01
Phosphatase and Tensin Gene Associated with Features of Aggressive Prostate Cancer
32
37
EN
Mojtaba
Saadati
0000-0001-7199-3167
Imam Hossein University, Tehran, Iran
saadati1-m@yahoo.com
Saeed
Tamehri
0000-0001-7803-5850
Urology Research Center, Tehran University of Medical Science, Tehran, Iran
saidtaheri1993@gmail.com
Mohsen
Pour Kamali
Urology Research Center, Tehran University of Medical Science, Tehran, Iran
m-pourkamali@yahoo.ca
Diana
Taheri
0000-0002-8131-1120
Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
diana1380@yahoo.com
10.22034/tru.2021.276823.1062
<strong>Introduction</strong><br />The current study examined the clinical impacts of phosphatase and tensin (PTEN) expression in prostate cancer (PCa) using immunohistochemistry.<br /><strong>Methods</strong><br />50 patients with mean age of 66.4±7.3 years who had undergone prostatectomy surgery with the diagnosis of PCa, were enrolled in the study. We collected 50 paraffin blocks from the malignant part and 50 paraffin blocks from the healthy part of each patient’s prostate. We considered malignant and healthy parts as the case and the control, respectively. Clinical and pathological information of the patients were gathered and their associations with PTEN status were assessed using odds ratios (ORs) analysis.<br /><strong>Results</strong><br />The significant associations between tumor stage, perivascular invasion, perineural invasion, marginal involvement, extraprostatic extension, and biochemical recurrence (as assed by post-surgical prostate-specific antigen (PSA)) and PTEN expression were detected. For patients negative for PTEN, the odds ratio of the higher stage, perivascular invasion, perineural invasion, marginal involvement, and extraprostatic extension in comparison to patients positive for PTEN were estimated 7.5 (95%CI: 2.01,27.86), (95%CI: 1.65-25.57), 7.8 (95%CI:1.54-40.09), 9.78 (95%CI:2.33-41.08), and 4.84 (95%CI:1.07-21.84), respectively. Concerning biochemical recurrence, ORs was calculated 0.30 (95%CI:0.09-1.02) for PTEN positive patients compare to PTEN negative patients.<br /><strong>Conclusions </strong><br />Since PTEN loss was associated with features of aggressive PCa, it can be concluded that loss of PTEN would lead to more aggressive PCa and thereby, lower clinical outcomes.
Prostate Cancer,Phosphatase,Tensin,Prostate-Specific Antigen,Biochemical recurrence
http://www.transresurology.com/article_128689.html
http://www.transresurology.com/article_128689_05a2cf624e984786917ca32b8a51fde0.pdf
Urology Research Center, Tehran University of Medical Sciences
Translational Research in Urology
2717-042X
3
1
2021
01
01
Management of a Lost Stone During Laparoscopic Ureterolithotomy: Video Article
38
39
EN
Alimohammad
Fakhr Yasseri
0000-0003-2084-2814
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
yasseri_2006@yahoo.com
Abdolreza
Mohammadi
0000-0002-0483-2635
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
drfyasseri@gmail.com
Seyed Mohammad Kazem
Aghamir
0000-0003-1611-0362
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
urc@tums.ac.ir
10.22034/tru.2021.278483.1063
<strong>Introduction</strong><br />Laparoscopic ureterolithotomy (LU) is a viable option for large ureteral stones (1, 2). The lost stone during laparoscopy is a rare event and most reports are in gallstone surgeries. Most experts recommended that the lost gallstone should be extracted from the abdominal cavity to prevent abscess formation but in laparoscopic ureterolithotomy with lost stone the optimal management is controversial (3-5). We report our experience with a lost ureteral stone during laparoscopy and the technique that was successful to find it.<br /><strong>Case presentation</strong><br />The patient was a 28-year-old man, presented with a 22 millimetres stone in the proximal part of the left ureter. The spiral computed tomography scan revealed severe hydronephrosis. The patient was positioned in the left flank and camera port inserted in the lateral border of rectus muscle then two 5 mm working ports inserted in the left upper quadrant and left lower quadrant, respectively. The ureterolithotomy process was performed uneventfully with Double-J stent insertion, but during the extraction of stone from 10 mm port, the stone was lost in abdominal space due to rupture of our endobag (which was a finger of a surgical glove). We extract the lost stone with stepwise searching of the dependent part of the abdominal cavity and found the stone in the dependent part of the right lower quadrant. The operative time was 165 minutes. The patient had no complication in the Post-operative course, the Foley catheter was removed on post-operative day 2 and the drain was removed on post-operative day 3. The patient was discharged home at post-operation day 4 and stent removed four weeks later.<br /><strong>Conclusions</strong><br />We believe that any effort should be performed to extract lost stone in laparoscopic ureterolithotomy cases due to the potential risk of abscess formation and the probability of misleading imaging in the future follow-up of patients.
Ureteral Stone,Laparoscopy,Ureterolithotomy
http://www.transresurology.com/article_128690.html
http://www.transresurology.com/article_128690_0c0e1becf1d471040629114aef11a4c6.pdf